Top Markets
#1 Helium Helium +109.80%
#2 MowCat MowCat +84.82%
#3 Seeker Seeker +49.80%
#4 UnifAI Network UnifAI Network +35.50%
#5 TENDIES TENDIES +30.52%
#6 Zylo Ecosystem Zylo Ecosystem +22.07%
#7 Tensor Tensor +21.07%
#8 Pons Pons +19.96%
#9 MarsCoin MarsCoin +17.58%
#10 pipedog pipedog +16.58%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Gyre Therapeutics, Inc. Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

GYRE
Classement en actions #11143
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering,... Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Prix de l'action
$6.61
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$736.94M
Changement (1 jour)
-1.05%
Changement (1 an)
-14.60%
Pays
US
Échange Gyre Therapeutics, Inc. (GYRE)

Catégorie

Healthcare
Historique du rendement du dividende pour Gyre Therapeutics, Inc. (GYRE)
Le rendement du dividende (TTM) de Gyre Therapeutics, Inc. (symbole boursier : GYRE) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Gyre Therapeutics, Inc. (GYRE) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH